Medical Oncologist
Metastatic breast cancer
Why receptors are re-tested on a metastatic biopsy
Breast cancer can change as it spreads. A biopsy of the new area confirms it is breast cancer and re-checks hormone receptors and HER2, which can differ from the original result and open or close treatment options. This page explains why and what to expect.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Why are receptors tested again when breast cancer spreads?
- What a new biopsy can tell your team
- How receptor changes can affect treatment, in general terms
- The vocabulary, in plain language
- Honest limits of receptor re-testing
- What a metastatic biopsy usually involves
- Weighing up whether to have a new biopsy
- Questions to ask about your new biopsy results
- What people assume about re-testing
- Common questions about receptor re-testing
The short answer
Why are receptors tested again when breast cancer spreads?
When breast cancer comes back or spreads, doctors usually recommend a biopsy of the new area, if it can be reached safely, and test it again for oestrogen receptors, progesterone receptors and HER2. These three markers guide almost every treatment decision in breast cancer. The reason for re-testing is that cancer can change over time. Some of the cells that survive earlier treatment may behave differently from the original cancer. A cancer that was hormone receptor positive may now show low or no hormone receptors, a cancer that was HER2-negative may now be HER2-positive or HER2-low, and the reverse can also happen. Studies suggest a change in at least one marker is found in a meaningful minority of people, commonly reported as somewhere between one in ten and one in three depending on the marker. A biopsy also confirms that the new spot is breast cancer rather than a different cancer, an infection or a harmless condition, which matters because treatment differs completely. When the result differs, treatment is usually planned around the most recent findings.
What is tested
The laboratory rechecks hormone receptors and HER2, and may also look at the proportion of dividing cells or, for some people, genetic changes in the cancer that point to additional treatment options.
When a biopsy is not possible
If the new spot is too deep or risky to reach, treatment may be based on the original results, scan findings and sometimes a blood test that looks for cancer DNA.
Ask about your results
Request copies of both the original and new pathology reports, so you can see whether anything has changed.
This page gives general information only. Your oncologist will explain your own results.The reasons
What a new biopsy can tell your team
Each finding can change the treatment plan.
It confirms the diagnosis
The new spot is breast cancer, not another cancer, infection or a benign change.
Hormone receptor status
Shows whether hormone therapy is still likely to help.
HER2 status
Shows whether HER2-targeted treatment, including options for HER2-low cancer, may be suitable.
HER2-low results can open new options.Extra tests
Some people have genetic testing of the cancer or of inherited genes.
These may include
- Tumour genetic changes that guide targeted treatment
- Inherited gene testing such as BRCA
- Markers used for immunotherapy decisions
Not sure whether this applies to you?
Ask an oncologistPossible changes
How receptor changes can affect treatment, in general terms
Change found
What it may mean
Hormone positive becomes negative
Hormone therapy is less likely to help; other treatments considered
Hormone negative becomes positive
Hormone therapy may become an option
HER2-negative becomes positive
HER2-targeted treatment may be added
HER2 zero becomes HER2-low
Treatments designed for HER2-low cancer may be considered
No change
Treatment is chosen based on the same markers and previous treatment
Words you will hear
The vocabulary, in plain language
- Receptor discordance
- When receptor results in the new biopsy differ from the original cancer.
- Oestrogen receptor (ER)
- A marker showing the cancer uses oestrogen to grow.
- HER2
- A protein that can drive cancer growth when present in large amounts.
- HER2-low
- Cancer with small amounts of HER2, not enough to be called HER2-positive.
- Re-biopsy
- A biopsy taken from a new or growing area of cancer.
- Liquid biopsy
- A blood test that looks for cancer DNA shed into the bloodstream.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being straight with you
Honest limits of receptor re-testing
Re-testing gives valuable information, but it is not perfect, and results need to be read carefully by an experienced team.
One sample, one moment
A biopsy shows the cells in one spot at one time. Other areas of cancer in the body may behave differently, which is why doctors also watch how the cancer responds to treatment.
Bone samples are harder to test
Biopsies from bone often need softening with chemicals before testing, which can affect some results. Soft tissue samples, such as from the liver or a lymph node, are preferred when available.
Testing differences
Results close to a cut-off, especially for HER2-low, can vary between laboratories. A second review of the slides may be requested.
Previous treatment can affect results
Recent treatment can change how cells look, so timing of the biopsy matters.
What this page cannot tell you
It cannot interpret your report. Ask your oncologist what your results mean for your plan.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
The procedure
What a metastatic biopsy usually involves
Most biopsies of metastatic areas are done with a needle under scan guidance and do not need an operation or an overnight stay.
Choosing the site
Your team picks the area that is safest to reach and most likely to give a good sample, such as a lymph node, liver spot, skin nodule or bone.
During the biopsy
Ultrasound or CT guides a thin needle to the area after local anaesthetic. Several small cores are taken. You may feel pressure or a brief ache.
Afterwards
You rest for a short time while staff check for bleeding. Mild soreness is common. Report fever, heavy bleeding or increasing pain.
Waiting for results
Receptor results often take one to two weeks. Genetic tests on the cancer can take longer. Your team may start or continue treatment while waiting if needed.
Making decisions
Weighing up whether to have a new biopsy
Many people wonder whether another procedure is worth it when scans already show spread. For most, the information gained is worth the small risk.
Reasons a biopsy is recommended
It may reveal a new treatment option, avoid a treatment that is unlikely to work, or show that the new spot is not cancer at all.
Reasons it may be skipped
If the area is very risky to reach, you are too unwell, or the result would not change the plan, your team may decide against it.
Talking it through
Ask what the biopsy could change, what the risks are for the chosen site, and what would happen if you did not have it. It is your decision to make with your team.
At your appointment
Questions to ask about your new biopsy results
Pathology reports are full of technical terms. Bringing written questions, and a relative to take notes, helps you understand what the results mean for your treatment.
About the results
Has anything changed compared with my original cancer? Are the hormone receptor and HER2 results clearly positive or negative, or close to a cut-off? Would a second review of the slides be useful?
About treatment
Does this result open any new treatment options, or rule any out? Should genetic testing of the cancer, or inherited gene testing, be done now?
About timing
How long will the results take, and will treatment start or continue while we wait for them?
About the future
If the cancer grows later on treatment, would another biopsy be recommended, and what would it look for?
Commonly believed
What people assume about re-testing
Once hormone positive, always hormone positive.
Receptors can change when cancer spreads, which is why re-testing is advised.
A biopsy makes cancer spread.
Needle biopsies are safe and do not make cancer spread.
Scans are enough to plan treatment.
Scans show where cancer is, but not its receptors.
A change in receptors means the lab made a mistake.
True biological change is well recognised, though second reviews can help near cut-offs.
Questions we are asked
Common questions about receptor re-testing
Is a re-biopsy always needed?
It is recommended when a new area can be reached safely, especially at first recurrence. Your team decides case by case.
Which result counts if they differ?
Treatment is usually guided by the most recent result, while considering the original too.
Can a blood test replace a biopsy?
A liquid biopsy can find some genetic changes but cannot test hormone receptors or HER2 protein levels.
Can I ask for a slide review?
Yes. Your team can send slides to another laboratory for a second opinion.
Is a bone biopsy reliable?
It can be, but soft tissue samples usually give more reliable receptor results.
Will I need another biopsy later?
Sometimes, if cancer grows on treatment and new options depend on the result.
Can I get a second opinion?
Yes. Bring both old and new pathology reports.
Who explains the report?
Your oncologist, who can go through each marker with you.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- American Society of Clinical Oncology — Recommendations on disease management for patients with advanced HER2-positive breast cancer
- European Society for Medical Oncology — Metastatic breast cancer clinical practice guideline
- National Cancer Institute — Hormone therapy for breast cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.